<DOC>
	<DOCNO>NCT02623582</DOCNO>
	<brief_summary>Pilot open-label study estimate feasibility , safety efficacy intravenously administer , RNA electroporated autologous T cell express anti-CD123 chimeric antigen receptor express tandem TCR 4-1BB ( TCR /4-1BB ) costimulatory domain ( refer RNA CART123 ) Acute Myeloid Leukemia ( AML ) subject .</brief_summary>
	<brief_title>CD123 Redirected Autologous T Cells AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Male female subject 18 year age old AML available curative treatment option use currently available therapy Subjects must suitable stem cell donor available may donate cell subject need undergo allogeneic HCT . Donor may match mismatch must find suitable accord institution 's standard criterion . Subjects second subsequent relapse , relapse refractory salvage , persistent disease least two line therapy . . Subjects relapse disease prior allogeneic HCT ( myeloablative nonmyeloablative ) eligible meet inclusion criterion . Have experience graft rejection ( evidence donor cell STR analysis 2 occasion separate least 1 month ) , OR : ii . Donor cell present active GVHD , subject require immunosuppression 6 month transplant Subjects must evaluable disease define &gt; 5 % blast marrow aspirate biopsy , extramedullary disease ( CNS involvement prohibit ) , least 20 % blast peripheral blood within 2 week prior enrollment . Note : subject second subsequent relapse consider evaluable disease even without meet morphologic criterion find persistent recurrent diseaseassociated molecular cytogenetic abnormality . Creatinine &lt; 1.6 mg/dl ALT/AST must &lt; 5 x upper limit normal unless related disease Bilirubin &lt; 2.0 mg/dl , unless subject Gilbert 's syndrome ( â‰¤3.0 mg/dL ) ; ECOG Performance status 02 . Left ventricular ejection fraction &gt; 40 % confirm ECHO/MUGA Written inform consent give . Subjects reproductive potential must agree use acceptable birth control method . Exclusion criterion : Pregnant lactate woman . The safety therapy unborn child know . Female study participant reproductive potential must negative serum pregnancy test enrollment . A urine pregnancy test perform within 48 hour infusion . HIV infection . Active hepatitis B hepatitis C infection . Concurrent use systemic steroid immunosuppressant medication . Recent current use inhale steroid physiologic replacement hydrocortisone exclusionary . Absolute lymphocyte count &lt; 500/uL Any uncontrolled active medical disorder would preclude participation outline . Subjects sign symptom indicative CNS involvement . A CNS evaluation perform clinically appropriate rule CNS involvement . Known history allergy hypersensitivity study product excipients ( human serum albumin , DMSO , Dextran 40 ) . Class III/IV cardiovascular disability accord New York Heart Association Classification . Patients known history prior diagnosis optic neuritis immunologic inflammatory disease affect central nervous system Subjects clinically apparent arrhythmia , arrhythmias stable medical management , within 2 week Screening/Enrollment visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>